Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
632 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Xiusong Qiu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal